The threat of a pandemic triggered by a new 'flu strain that has killed 103 people in Mexico will provide a windfall for some makers of drugs and vaccines.
Shares in Australia's Biota Holdings Ltd
Relenza, known generically as zanamivir, is one of two drugs, along with Roche Holding AG's
Tamiflu, given as a convenient tablet, is expected to be in greatest demand and shares in Roche were indicated 3.5 percent higher in Zurich on Monday morning.
Tamiflu was originally invented by U.S. biotech company Gilead Sciences Inc
The 'flu outbreak, which poses the biggest risk of a large-scale pandemic since avian 'flu surfaced in 1997, will also fuel demand for vaccines from major producers like Sanofi-Aventis SA
Shares in U.S. biotech company Novavax Inc
(Reporting by Ben Hirschler; Editing by Greg Mahlich)